|Day Low/High||6.18 / 6.35|
|52 Wk Low/High||2.22 / 6.68|
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ABAC, C, CARA, CATM, CNSI, NNA, OSTK, PGTI, RUTH, SLB, SODA, TGS Downgrades: PDEX Initiations: AKER Read on to get TheStreet Quant Ratings' detailed report:
Pro-Dex (PDEX) has been upgraded by TheStreet Ratings from Sell to Hold with a ratings score of C.
Upgrades: CENX, CKSW, PAR, PBA, PDEX, PRCP, RLD, SSFN, TSU, ZIXI Downgrades: None Initiations: None Read on to get TheStreet Quant Ratings' detailed report:
Upgrades: AIV, ATTU, CSC, EXH, GOLD, LYV, PRLB, SBUX, TREX Downgrades: ABAX, EPB, HAYN, MCY, PDEX, PRGX, SSI, WMGI Initiations: ERA Read on to get TheStreet Quant Ratings' detailed report:
Upgrades: CCL, CSIQ, DF, HTH, NNA, PDEX, POWR, SATS, TCX Downgrades: BERK, CRAY, CSBK, MTOR, OIS, PAM, RST, UNIS Initiations: RGLS Read on to get TheStreet Quant Ratings' detailed report:
Pro-Dex (Nasdaq:PDEX) has been upgraded by TheStreet Ratings from a hold to buy.
All it takes is one big drug approval, a buyout from big pharma or a plump contract from a major provider to send shares of penny stocks like these soaring.
Northfield Labs rises 10% after a recommendation that its PolyHeme trial continue without changes.
Jo-Ann Stores posts a wider-than-expected loss after markdowns and promotions crushed margins.